Two are better than one
05/08/22 -"Merck reported another estimate-beating quarter. We hope investors will not be too upset when Merck’s performance no longer meets expectations. This might take quite a while as a second driver has ..."
Pages
67
Language
English
Published on
05/08/22
You may also be interested by these reports :
30/09/26
Lundbeck, as per Bloomberg, is pursuing endocrine- and neurology-focused Xeris Biopharma, whose market cap is c.28% of that of Lundbeck. Considering ...
24/09/26
A years/decades long search for revolutionary multi-blockbuster drug(s), a phenomenal run for some years and then concerns sprout around ...
21/09/26
Novo’s CMD announcements, including the diversification plan and a vague mid-term sales target, disappointed investors. Against the backdrop of ...
21/09/26
Siegfried’s (Buy, Switzerland) post-Covid success story has been nipped in the bud by three years of low-single-digit (LSD) growth (in CHF). ...